The DOI matches its Crossref record.
Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation
Open accessAbstract
Donor-specific HLA antibodies (DSA) have a negative impact on kidney graft survival. Therefore, we analyzed the occurrence of DSA and antibody-mediated rejection (AMR) in patients from two prospective randomized trials in our center. At 3-4.5 months posttransplant 127 patients were randomized to continue cyclosporine or converted to everolimus therapy. The presence of DSA was prospectively assessed using Luminex assays. AMR was defined according to the Banff 2009 classification. Antibody screening was available in 126 patients with a median follow-up of 1059 days. Seven out of 65 (10.8%) patients on cyclosporine developed DSA after a median of 991 days. In comparison, 14/61 patients (23.0%) randomized to everolimus developed DSA after 551 days (log-rank: p = 0.048). Eight patients on everolimus compared to two patients on cyclosporine developed AMR (log-rank: p = 0.036). Four of 10 patients with AMR-all in the everolimus group-lost their graft. A multivariate regression model revealed everolimus, >3 mismatches and living donor as significant risk factors for DSA. Acute rejection within the first year, >3 mismatches, everolimus and living donor were independent risk factors for AMR. This single center analysis demonstrates for the first time that everolimus-based immunosuppression is associated with an increased risk for the development of DSA and AMR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tait, B. D., Süsal, C., Gebel, H. M., Nickerson, P. W., Zachary, A. A., Claas, F. H. J., Reed, E. F., Bray, R. A., Campbell, P., Chapman, J. R., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e31827a19cc · Cited by 787
Self-citationDiagnosis and Management of Antibody-Mediated Rejection: Current Status and Novel Approaches
Djamali, A., Kaufman, D. B., Ellis, T. M., Zhong, W., Matas, A., & Samaniego, M. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12589 · Cited by 369
Neuberger, J. M., Bechstein, W. O., Kuypers, D. R. J., Burra, P., Citterio, F., De Geest, S., Duvoux, C., Jardine, A. G., Kamar, N., Krämer, B. K., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001651 · Cited by 315
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Viana, S. D., Reis, F., & Alves, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3693625 · Cited by 48
Metadata
- Authors
- Liefeldt, L., Brakemeier, S., Glander, P., Waiser, J., Lachmann, N., Schönemann, C., Zukunft, B., Illigens, P., Schmidt, D., Wu, K., Rudolph, B., Neumayer, H.-H., & Budde, K.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 12
- Issue
- 5
- Pages
- 1192-1198
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1541756612
- Cited by
- 244
- References
- 0
- FWCI
- 19.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation. https://app.cochat.ai/papers/10.1111/j.1600-6143.2011.03961.x
- The paper
- Liefeldt, L., Brakemeier, S., Glander, P., Waiser, J., Lachmann, N., Schönemann, C., Zukunft, B., Illigens, P., Schmidt, D., Wu, K., Rudolph, B., Neumayer, H.-H., & Budde, K. (2012). Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2011.03961.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.